Payment overview · 2025
General Payments
$1,256.10
34 reported records · 13 companies
Healthcare provider profile · identity verified
Basel Brikho, MD
Allopathic & Osteopathic Physicians|Pediatrics · LATHRUP VILLAGE, MI · NPI 1285721514
Verified facts
What the public records show
CMS Open Payments records show Basel Brikho, MD received $1,256.10 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $274.98 | 21.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.02 | 18.6% | 7 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.22 | 10.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $121.35 | 9.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$118.10 | 9.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.12 | 7.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.86 | 6.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.46 | 5.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.09 | 4.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.32 | 1.9% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $22.47 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.1% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $13.80 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,256.10 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $137.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $129.18 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $121.35 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $118.10 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $76.34 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.46 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.21 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $57.21 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $57.09 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
137 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1487 | 277 |
| Omeprazole | Omeprazole | 757 | 126 |
| Lisinopril | Lisinopril | 597 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 579 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 559 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 519 | 92 |
| Metformin Hcl | Metformin Hcl | 478 | 87 |
| Simvastatin | Simvastatin | 462 | 78 |
| Losartan Potassium | Losartan Potassium | 442 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 76 |
| Montelukast Sodium | Montelukast Sodium | 402 | 69 |
| Glimepiride | Glimepiride | 392 | 62 |
| Metformin Hcl Er | Metformin Hcl | 391 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 339 | 80 |
| Famotidine | Famotidine | 309 | 68 |
| Gabapentin | Gabapentin | 300 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 282 | 45 |
| Ezetimibe | Ezetimibe | 279 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 46 |
| Azithromycin | Azithromycin | 248 | 180 |
| Furosemide | Furosemide | 239 | 51 |
| Hydrocortisone | Hydrocortisone | 230 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 48 |
| Ibuprofen | Ibuprofen | 218 | 60 |
| Celecoxib | Celecoxib | 211 | 34 |
| Allopurinol | Allopurinol | 210 | 39 |
| Eliquis | Apixaban | 196 | 26 |
| Alendronate Sodium | Alendronate Sodium | 184 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 32 |
| Jardiance | Empagliflozin | 163 | 25 |
| Januvia | Sitagliptin Phosphate | 162 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 158 | 40 |
| Repaglinide | Repaglinide | 150 | 25 |
| Potassium Chloride | Potassium Chloride | 147 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 28 |
| Linzess | Linaclotide | 137 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 127 | 38 |
| Meloxicam | Meloxicam | 122 | 44 |
| Atenolol | Atenolol | 120 | 22 |
| Carvedilol | Carvedilol | 120 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 115 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 111 | 42 |
| Tradjenta | Linagliptin | 110 | 12 |
| Farxiga | Dapagliflozin Propanediol | 106 | 17 |
| Meclizine Hcl | Meclizine Hcl | 105 | 41 |
| Donepezil Hcl | Donepezil Hcl | 100 | 16 |
| Mupirocin | Mupirocin | 94 | 39 |
| Baclofen | Baclofen | 91 | 33 |
| Prednisone | Prednisone | 91 | 56 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 14 |
| Mirtazapine | Mirtazapine | 85 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 13 |
| Colchicine | Colchicine | 79 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 14 |
| Finasteride | Finasteride | 72 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 11 |
| Pregabalin | Pregabalin | 70 | 12 |
| Alprazolam | Alprazolam | 67 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 16 |
| Ammonium Lactate | Ammonium Lactate | 66 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 62 | 18 |
| Bumetanide | Bumetanide | 59 | suppressed |
| Cephalexin | Cephalexin | 58 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 45 |
| Spironolactone | Spironolactone | 55 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Procto-Med Hc | Hydrocortisone | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 50 | 45 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 38 |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 32 |
| Ketoconazole | Ketoconazole | 40 | 11 |
| Nitroglycerin | Nitroglycerin | 40 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Prolia | Denosumab | 38 | 22 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 34 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Lidocaine | Lidocaine | 34 | 12 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Nystatin | Nystatin | 33 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | 11 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,256.10 · 34 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, EVKEEZA, FARXIGA, KISUNLA, KRYSTEXXA, LINZESS, MOUNJARO, Ozempic, PYRUKYND, REPATHA, RHYTHM EXPRESS, Rybelsus, SHINGRIX, SYMPLICITY G3, UZEDY, VOQUEZNA, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error